New Medicare rules on home ventilation could cut off care for the sickest COPD patients

I've spent my career caring for people with severe lung disease, and one thing has stayed with me: when breathing becomes difficult, nothing else matters. I think about that whenever I think about one of my patients — I'll call her Martha.

Martha has severe Chronic Obstructive Pulmonary Disease (COPD) complicated by chronic respiratory failure. Her lungs no longer efficiently remove carbon dioxide from her body, causing it to build up in her bloodstream. It's a condition called hypercapnia and it affects some of the sickest people living with COPD. The impact on quality of life is devastating.

By the time I met her, Martha couldn't walk across her home without becoming short of breath. Carrying on a conversation was exhausting. She was in and out of the hospital and lived with the constant fear that her next breath wouldn't come as easily as the last. Then she began using non-invasive ventilation, or NIV, at home. The change was remarkable.

Her breathing improved. She became more active and could leave the house again to walk her dogs. She regained a measure of confidence that chronic illness had slowly taken away. Martha put it more simply than any physician ever could. "When you can't breathe, it's scary," she told my team. "NIV helped me not be scared anymore."

I've practiced pulmonary medicine for more than 30 years. I've worked in intensive care units, cared for thousands of patients with advanced lung disease, and published research on COPD and home ventilation. In that time, I've seen plenty of treatments that offer modest benefits. Home ventilation is a whole other level of transformative medical equipment.

NIV can be lifesaving for patients with hypercapnic COPD. These patients represent a small fraction of the COPD population, roughly the sickest 5%, but their needs are among the most urgent. Studies show NIV can reduce hospitalizations and lower mortality rates.

In fact, among hypercapnic COPD patients receiving NIV at home, its use is associated with a 40% reduction in the risk of death during the first year of treatment. In my patients, I have seen outcomes that would otherwise be impossible to achieve without access to ventilation in the home setting.

This isn't a convenience device. It isn't prescribed casually. Patients use NIV under the guidance of physicians who understand the severity of their disease and the complexity of their care. That's why many of us in the pulmonology and respiratory care communities are concerned about the new Medicare coverage guidance for NIV.

To be clear, the updated national coverage decision included several positive reforms. But questions remain about the continuing use requirements patients must satisfy to maintain access to these devices.

Under the policy, patients are expected to meet specific usage thresholds during each 30-day period. The intention is understandable: Medicare wants to ensure patients are using the therapies that benefit them. The problem is that medicine rarely works in neat little boxes.

Patients get sick. They develop infections. They are hospitalized. Some struggle during periods of decline before stabilizing again. Yet the current guidance provides little direction about what should happen when patients demonstrate clinical benefit but fall short of rigid adherence requirements.

Just as concerning, the adherence thresholds themselves are arbitrary — not based on published outcomes data. Studies have not established four hours of use per 24-hour period as the minimum threshold required to achieve meaningful clinical benefit in this population. At the bedside, physicians don't make decisions this way. What worries me most is the possibility that doctors and suppliers are being told to discontinue NIV for patients who still need it simply because they failed to check a regulatory box. That isn't consistent with good medicine.

Patients and families are left wondering whether the treatment keeping them stable today could suddenly be taken away tomorrow. For people already living with severe respiratory disease, that uncertainty creates its own burden. The confusion extends beyond patients. Physicians and equipment suppliers have been left without clear instructions about how usage data should be reported or who bears responsibility for collecting it. Suppliers are expected to comply with prospective billing requirements without any way to know whether patients will ultimately satisfy usage standards, creating an almost impossible situation to navigate.

But for patients, the stakes are far higher than administrative challenges. For someone like Martha, losing access to NIV doesn't mean giving up a helpful gadget. It means losing the treatment that extends her life, while allowing her to remain at home and avoid repeated hospitalizations. With NIV, Martha can live with less fear. Patients, physicians and suppliers need immediate clarification before confusion and unintended consequences place vulnerable people at risk.

Payment policies work best when they reflect clinical realities and patient outcomes. When they don't, vulnerable patients pay the price.

Dr. William D. Frazier is a board-certified pulmonologist and the Chief Medical Officer (CMO) at VieMed Healthcare. He leads the company's clinical research and education, advocating heavily for the early adoption of non-invasive ventilation at home (NIVH) to treat patients with COPD and chronic respiratory failure.